期刊存档
2318株结核分枝杆菌耐多药性分析
骆科文，刘隆平，张庭梅，唐发琴，王燕，陈红梅骆科文、刘隆平、张庭梅、唐发琴、王燕、陈红梅，贵阳市肺科医院检验科，550006
基金项目： 上海市结核病(肺)重点实验室开放基金(2007-07)
摘 要:目的 探讨贵阳市肺科医院住院结核病患者中的耐药情况，为临床诊断和治疗耐多药结核病提供可靠的科学依据。方法 对2004年1月至2009年8月住院患者的临床分离株进行菌型鉴定后，进行药物敏感性试验，分析不同类型结核病患者的耐药情况。结果 2318株结核分枝杆菌耐多药率为23.8%，初始耐多药率为12.1%，获得性耐多药率为63.8%。结论 目前结核病患者耐药率较高，应尽快加强耐药结核病患者的防治工作，减少和避免耐多药结核病患者的产生。
关键词:分枝杆菌，结核； 抗药性，多种，细菌； 微生物敏感性试验
Analysis of 2318 Mycobacterium tuberculosis resistant to multiple drugs
LUO Ke-wen，LIU Long-ping，ZHANG Ting-mei，TANG Fa-qin，WANG Yan，CHEN Hong-mei.Guiyang Pulmonary Hospital，Guizhou 550006，China
Abstract:Objective To explore our hospital situation in the drug resistance of tuberculosis (TB)patients for clinical diagnosis and treatment (MDR-TB)，the purpose was to provide a reliable scientific evidence.Methods The clinical isolates serotype of hospitalized patients during was identified，conducted drug susceptibility tests and analyzed different types of tuberculosis drug resistance from January 2004 to August 2009.Results The rate of 2318 multi-drug resistant Mycobacterium tuberculosis was 23.8%，the initial multi-drug resistant rate was 12.1% and acquired multidrug resistance rate was 63.8%.ConclusionsIn our hospital，high rates of TB drug resistance，drug-resistant TB patients as soon as possible to strengthen prevention and control，reduce and prevent the emergence resistant TB patients.
Key words:Mycobacterium tuberculosis； Drug resistance，multiple，bacterial； Microbial sensitivity tests
文献标引:骆科文，刘隆平，张庭梅，唐发琴，王燕，陈红梅.2318株结核分枝杆菌耐多药性分析[J/CD].中华临床医师杂志：电子版,2010,4(7):928-930.
参考文献:
[1] WHO/IUATLD.Guidelines for serveilance of drug resistance in tuberculosis.Geneva：WHO,1997：216.
[2] 中国防痨协会.结核病诊断细菌学检验规程.中国防痨杂志，1996,18(2)：78-81.
[3] 柳正卫，何海波，缪梓萍，等.984株结核分枝杆菌耐药情况分析.中国防痨杂志，2007,29(2)：167-170.
[4] 安慧茹，王巍.基因突变与结核分支杆菌对喹诺酮类药物耐药性的研究进展.中国防痨杂志，2004,26(1)：53-56.
[5] Reichman LB. Multidrug resistance in the world：the present situation.Chemotherapy,1996,42 Suppl 3：2-9.[PubMed]
[6] Crofton J，Chaulet P，Maher D，et al.Guidelines for the management of drug resistant tubercubosis.Geneva：WHO/TB,1997：26.
[7] Maranetra KN.Quinolones and Multidrug-Resistant Tuberculosis.Chemotherapy,1999,45 Suppl 2：12-18.
